Abbott acquires co-marketing rights to arthritis drug

Article Abstract:

Miles D. White, Abbott Laboratories' new CEO admits his firm needs more new drugs in its pipeline, one reason for the co-marketing deal for selling German-made Mobic in the U.S. Another departure for the Illinois-based pharmaceuticals firm will be a more aggressive approach to mergers. Mobic is an arthritis pain reliever made by Boehringer Ingelheim GmbH. But it is not known whether the new drug will be effective without the gastrointestinal problems that most current arthritis drugs can cause. This is a chief reason for the success of Celebrex co-marketed by Monsanto and Pfizer .

Comment:

Signed co-marketing deal with Abbott Labs to sell Mobic in the US

Foreign operations, Germany, Strategic alliances, Geographic, Licensing/Sales Agreements, Contracts, ABT, Abbott Laboratories (Abbott Park, Illinois), Boehringer Ingelheim GmbH

---

Monsanto arthritis-pain drug, Celebrex, surpasses Viagra's early sales success

Article Abstract:

Monsanto's Celebrex for arthritis pain without causing severe stomach distress is showing signs of becoming the biggest selling prescription drug ever. The prediction is arrived at by comparing its number of prescriptions written to the number written for Viagra, currently the leader in early sales. Celebrex in only seven weeks has captured over 20% of the arthritis pain relief market.

Comment:

Celebrex can celebrate current market lead

Sales & consumption, Statistics, Monsanto Co., MTC, Antiarthritic agents

---

Similar abstracts:

• Abstracts: Ford uses aggressive marketing approach in Thailand. Under pressure, GM takes its sales show on the road. GM puts strikes' cost at $1.18 billion, above analysts' estimates
• Abstracts: Scotts agrees to buy part of Monsanto unit in a $300 million deal. American Home, Monsanto to combine in a stock swap valued at $35.08 billion
• Abstracts: GM is closing rest of North American operations. GM seeks broad agreement in Flint strike talks
• Abstracts: Sepracor Inc. licenses the rights to a safer heartburn drug to J&J
• Abstracts: BP to acquire Amoco in huge deal spurred by low energy prices. Duke Energy agrees to pay $1.35 billion for gas unit of Union Pacific Resources

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.